PAN from M. paratuberculosis BioVector NTCC质粒载体菌种细胞基因保藏中心

PAN from M. paratuberculosis BioVector NTCC质粒载体菌种细胞基因保藏中心
Mycobacterium bovis BCG is currently the world's most widely used vaccine and has been given to more than three billion people, making it a very attractive prospect for the development of a live recombinant BCG (rBCG) multivaccine (1). The first generation of rBCG vaccines was developed in the 1990s as rBCG strains that expressed homologous and heterologous antigens from a wide range of pathogens (2–5). Stability of the heterologous (or native) gene(s) in BCG was usually obtained by cloning it on a plasmid or chromosomally integrative vector with expression achieved by placing it under the control of a range of mycobacterial promoters (2). The heat shock protein promoters (PHsp60 from BCG and PHsp70 from M. tuberculosis), the IS900 open reading frame promoter (PAN from M. paratuberculosis), and the mutated β-lactamase promoter (PBlaF* from M. fortuitum) are the ones used most
【Supplier来源】BioVector NTCC Inc.
TEL：+86-010-53513060
【Website网址】 http://www.biovector.net